Lista de obras - Mark R. Lackner - Dominio Público Uruguay

A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia

artículo científico publicado en 2016

Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110β.

artículo científico publicado en 2016

Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.

artículo científico publicado en 2009

Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake.

artículo científico publicado en 2008

Challenges and opportunities in the use of CTCs for companion diagnostic development.

artículo científico

Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer.

artículo científico publicado en 2014

Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors

artículo científico publicado en 2005

Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples.

artículo científico publicado en 2014

ERK inhibition overcomes acquired resistance to MEK inhibitors.

artículo científico publicado en 2012

Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068.

artículo científico publicado en 2013

Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib

artículo científico publicado en 2012

FOXO3a and β-catenin co-localization: double trouble in colon cancer?

artículo científico publicado en 2012

First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors

artículo científico publicado en 2015

GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway

artículo científico publicado en 2011

Genetic alterations and oncogenic pathways associated with breast cancer subtypes

artículo científico publicado en 2009

HGF as a circulating biomarker of onartuzumab treatment in patients with advanced solid tumors.

artículo científico publicado en 2013

High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing.

artículo científico

Identification of Endoglin as an epigenetically regulated tumour-suppressor gene in lung cancer

artículo científico publicado en 2015

In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.

artículo científico publicado en 2009

Mechanisms of acquired resistance to targeted cancer therapies.

artículo científico

Molecular biomarker analyses using circulating tumor cells

artículo científico publicado en 2010

Monitoring phosphoproteomic response to targeted kinase inhibitors using reverse-phase protein microarrays.

artículo científico publicado en 2012

PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance

artículo científico publicado en 2015

Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine

artículo científico publicado en 2015

Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.

artículo científico publicado en 2012

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.

artículo científico publicado en 2016

Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing

artículo científico publicado en 2014

Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways.

artículo científico publicado en 2010

TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer

scientific journal article

Targeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancers

artículo científico publicado en 2014

Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy.

artículo científico publicado en 2010

Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer.

artículo científico publicado en 2015

miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer

artículo científico publicado en 2011

Lista de obras de Mark R. Lackner

A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia

Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110β.

Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.

Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake.

Challenges and opportunities in the use of CTCs for companion diagnostic development.

Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer.

Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors

Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples.

ERK inhibition overcomes acquired resistance to MEK inhibitors.

Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068.

Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib

FOXO3a and β-catenin co-localization: double trouble in colon cancer?

First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors

GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway

Genetic alterations and oncogenic pathways associated with breast cancer subtypes

HGF as a circulating biomarker of onartuzumab treatment in patients with advanced solid tumors.

High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing.

Identification of Endoglin as an epigenetically regulated tumour-suppressor gene in lung cancer

In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.

Mechanisms of acquired resistance to targeted cancer therapies.

Molecular biomarker analyses using circulating tumor cells

Monitoring phosphoproteomic response to targeted kinase inhibitors using reverse-phase protein microarrays.

PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance

Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine

Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.

Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing

Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways.

TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer

Targeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancers

Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy.

Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer.

miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer